Relationship between metabolic syndrome and vitamin D level in patients with ankylosing spondylitis
Öz
Purpose: The purpose of this study is to reveal the relationship between the level of Vitamin D and the development of Metabolic Syndrome (MetS) in patients with Ankylosing Spondylitis (AS).
Materials and Methods: 67 AS patients were included in this cross-sectional descriptive study. Socio-demographic data, waist circumference and systolic blood pressure were evaluated. Fasting blood glucose, HDL cholesterol, Triglyceride and Vitamin D values were recorded. Diagnosis of MetS was made according to National Cholesterol Education Program’s Adult Treatment Panel (NCEP/ATP III). Disease activity and quality of life were assessed.
Results: In the present study, a significantly negative correlation was detected between Vitamin D levels and MetS in AS patients. HDL levels and Vitamin D levels were significantly lower in patients with MetS. Multiregression analysis showed that MetS was positively associated with BMI, Triglyceride level, fasting glucose and negatively associated with HDL cholesterol and Vitamin D.
Conclusion: This study shows that vitamin D may have a role in the development of MetS in patients with AS. However, more studies are needed to explain the relationship between vitamin D and metabolic syndrome in patients with ankylosing spondylitis.
Anahtar Kelimeler
Ankylosing Spondylitis, Anti-Tumor Necrosis Factor-Alpha, Cardiovascular Risk, Metabolic Syndrome, Vitamin D
Destekleyen Kurum
yoktur
Proje Numarası
yoktur
Kaynakça
- 1. Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127-37.
- 2. Daikh DI, Chen PP. Advances in managing ankylosing spondylitis. F1000Prime Reports. 2014;6:78.
- 3. Dessein PH, Stanwix AE, Moomal Z. Rheumatoid arthritis and cardiovascular disease may share similar risk factors. Rheumatology. 2001;40:703-4.
- 4. Divecha H, Sattar N, Rumley A, Cherry L, Lowe GD, Sturrock R. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison to non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond). 2005;109:171-6.
- 5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and Management of the Metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.
- 6. National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143–421.
- 7. Stern MP, Williams K, Gonza´lez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?. Diabetes Care. 2004;27(11):2676–81.
- 8. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–74.
- 9. Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med. 2002;165(5):670–6.
- 10. Gouni-Berthold I, Krone W, Berthold HK. Vitamin D and cardiovascular disease. Curr Vasc Pharmacol 2009;7(3):414–22.
